Recent News

• 05.28.2025 - KOL Webinar
• 05.28.2025 - KOL Webinar
• 05.20.2025 - Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
• 05.20.2025 - Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma
• 05.19.2025 - Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies
• 05.19.2025 - Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies
• 04.01.2025 - Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
• 04.01.2025 - Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
• 03.31.2025 - Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
• 03.31.2025 - Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Recent Filings

• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.24.2025 - DEF 14A Other definitive proxy statements
• 04.24.2025 - ARS Annual Report to Security Holders
• 04.24.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.31.2025 - 8-K Current report
• 03.31.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.31.2025 - EX-99.1 EX-99.1
• 03.27.2025 - 8-K Current report